## MOTHAFFAR RIMAWI

| | Title| Professor  
---|---  
Institution| Baylor College of Medicine  
Department| Department of Medicine  
Address| 7200 CAMBRIDGE  
Houston, TX 77030  
  
Email|
![](https://profiles.viictr.org/profile/modules/CustomViewPersonGeneralInfo/EmailHandler.ashx?msg=JKI94HLOQIn2S8Ho5G4%3d&rnd=16af458e-b517-4bfc-8da1-f512f30503f9)  
vCard| [Download
vCard](https://profiles.viictr.org/profile/modules/CustomViewPersonGeneralInfo/vcard.aspx?subject=269416)  
  
![](https://profiles.viictr.org/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx?NodeID=269416&cachekey=61cd8ff5-67cd-4231-ad38-ec4c814b2970)  
  

Other Positions| Title| Professor  
---|---  
Institution| Baylor College of Medicine  
Department| Duncan Cancer Center  
Division| Cancer Center  
  
  
  
  
![Collapse](https://profiles.viictr.org/Profile/Modules/PropertyList/images/minusSign.gif)
Research  

![Collapse](https://profiles.viictr.org/Profile/Modules/PropertyList/images/minusSign.gif)
research activities and funding

P50CA186784 (ZHANG, XIANG)Sep 19, 2014 - Jul 31, 2025NIH  
Translational Research in Breast Cancer  
Role: Co-Principal Investigator  
---  
  
* * *  
  
U10CA118735 (RIMAWI, MOTHAFFAR FAHED)Apr 10, 2006 - Jan 31, 2013NIH  
NSABP Participating Sites  
Role: Principal Investigator  
  
  
![Collapse](https://profiles.viictr.org/Profile/Modules/PropertyList/images/minusSign.gif)
Featured Content  

![Collapse](https://profiles.viictr.org/Profile/Modules/PropertyList/images/minusSign.gif)
Twitter

  
![Collapse](https://profiles.viictr.org/Profile/Modules/PropertyList/images/minusSign.gif)
Bibliographic  

![Collapse](https://profiles.viictr.org/Profile/Modules/PropertyList/images/minusSign.gif)
selected publications

Publications listed below are automatically derived from MEDLINE/PubMed and
other sources, which might result in incorrect or missing publications.
Faculty can
[login](https://profiles.viictr.org/loginOptions.aspx?pin=send&method=login&edit=true)
to make corrections and additions.

Newest | Oldest | Most Cited | Most Discussed | Timeline | Field Summary | Plain Text

PMC Citations indicate the number of times the publication was cited by
articles in PubMed Central, and the Altmetric score represents citations in
news articles and social media. (Note that publications are often cited in
additional ways that are not shown here.) Fields are based on how the National
Library of Medicine (NLM) classifies the publication's journal and might not
represent the specific topic of the publication. Translation tags are based on
the publication type and the MeSH terms NLM assigns to the publication. Some
publications (especially newer ones and publications not in PubMed) might not
yet be assigned Field or Translation tags.) Click a Field or Translation tag
to filter the publications.

  1. Freedman RA, Heiling HM, Li T, Trapani D, [Tayob N](https://profiles.viictr.org/profile/18883240), Smith KL, Davis R, Pereslete AM, DeMeo MK, Cotter C, Chen WY, Parsons HA, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko ME, O'Sullivan CC, Ashai N, Rauf Y, [Nangia JR](https://profiles.viictr.org/profile/266130), Burns RT, Savoie J, Wolff AC, Winer EP, **Rimawi MF** , Krop IE, Lin NU. Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022. Ann Oncol. 2024 Jul 06. PMID: [38977064](//www.ncbi.nlm.nih.gov/pubmed/38977064).

Citations:  Fields:

Neo Neoplasms

  2. Cheang MCU, **Rimawi M** , Johnston S, Jacobs SA, Bliss J, Pogue-Geile K, Kilburn L, Zhu Z, Schuster EF, Xiao H, Swaim L, Deng S, Lu DR, Gauthier E, Tursi J, Slamon DJ, Rugo HS, Finn RS, Liu Y. Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies. NPJ Breast Cancer. 2024 Jun 29; 10(1):54. PMID: [38951507](//www.ncbi.nlm.nih.gov/pubmed/38951507); PMCID: [PMC11217366](//www.ncbi.nlm.nih.gov/pmc/articles/PMC11217366).

Citations:

  3. Tarantino P, [Tayob N](https://profiles.viictr.org/profile/18883240), Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, **Rimawi M** , Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, [Mittendorf EA](https://profiles.viictr.org/profile/12583070), Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM, Consortium of the TBCRC Translational Investigators, TBCRC Translational Investigators. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024 Jun 27; JCO2302170. PMID: [38935923](//www.ncbi.nlm.nih.gov/pubmed/38935923).

Citations:  Fields:

Neo Neoplasms

  4. Ma CX, Suman VJ, Sanati S, Vij K, [Anurag M](https://profiles.viictr.org/profile/15619466), Leitch AM, Unzeitig GW, Hoog J, Fernandez-Martinez A, Fan C, [Gibbs RA](https://profiles.viictr.org/profile/269695), Watson MA, Dockter TJ, Hahn O, Guenther JM, [Caudle A](https://profiles.viictr.org/profile/12583102), Crouch E, Tiersten A, Mita M, Razaq W, Hieken TJ, Wang Y, **Rimawi MF** , Weiss A, Winer EP, [Hunt KK](https://profiles.viictr.org/profile/12582914), Perou CM, Ellis MJ, Partridge AH, Carey LA. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371. PMID: [38236590](//www.ncbi.nlm.nih.gov/pubmed/38236590); PMCID: [PMC10797521](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10797521).

Citations:  Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  5. Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, [Pataer A](https://profiles.viictr.org/profile/12582587), Lu D, Han D, [Malmberg E](https://profiles.viictr.org/profile/34768188), Chan DW, Wang X, Savage SR, Mao S, Yu J, Peng F, Yan L, Meng H, Maneix L, Han Y, Chen Y, Yao W, Chang EC, [Catic A](https://profiles.viictr.org/profile/6541051), Lin X, [Miles G](https://profiles.viictr.org/profile/18892308), [Huang P](https://profiles.viictr.org/profile/32901593), Sun Z, [Burt B](https://profiles.viictr.org/profile/8354542), Wang H, Wang J, [Yao QC](https://profiles.viictr.org/profile/268592), Zhang B, [Roth JA](https://profiles.viictr.org/profile/12583652), [O'Malley BW](https://profiles.viictr.org/profile/269511), Ellis MJ, **Rimawi MF** , [Ying H](https://profiles.viictr.org/profile/12583968), Chen X. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science. 2023 09 08; 381(6662):eabn4180. PMID: [37676964](//www.ncbi.nlm.nih.gov/pubmed/37676964); PMCID: [PMC10720158](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10720158).

Citations:
[2](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/37676964/citedby/) Fields:

Sci Science

Translation:HumansCells

  6. Hennessy MA, Leal JP, Huang CY, Solnes LB, Denbow R, Abramson VG, Carey LA, Liu MC, **Rimawi M** , Specht J, Storniolo AM, Valero V, Vaklavas C, Winer EP, Krop IE, Wolff AC, Cimino-Mathews A, Wahl RL, Stearns V, Connolly RM. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). J Nucl Med. 2023 11; 64(11):1690-1696. PMID: [37652539](//www.ncbi.nlm.nih.gov/pubmed/37652539).

Citations:  Fields:

Nuc Nuclear Medicine

Translation:Humans

  7. Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, **Rimawi MF** , Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, [Tayob N](https://profiles.viictr.org/profile/18883240), Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VA. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. 2023 10; 34(10):899-906. PMID: [37597579](//www.ncbi.nlm.nih.gov/pubmed/37597579); PMCID: [PMC10898256](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10898256).

Citations:
[3](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/37597579/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  8. Wang J, Saltzman AB, Jaehnig EJ, [Lei JT](https://profiles.viictr.org/profile/6998694), [Malovannaya A](https://profiles.viictr.org/profile/3010185), Holt MV, Young MN, **Rimawi MF** , Ademuyiwa FO, [Anurag M](https://profiles.viictr.org/profile/15619466), Kim BJ, Ellis MJ. Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Res Commun. 2023 08; 3(8):1551-1563. PMID: [37587913](//www.ncbi.nlm.nih.gov/pubmed/37587913); PMCID: [PMC10426551](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10426551).

Citations:  Translation:Humans

  9. [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), [Gutierrez C](https://profiles.viictr.org/profile/265496), De Angelis C, Davis R, Wang T, Pascual T, Selenica P, Sanchez K, Nitta H, Kapadia M, Pavlick AC, Galvan P, Rexer B, Forero-Torres A, Nanda R, Storniolo AM, Krop IE, Goetz MP, [Nangia JR](https://profiles.viictr.org/profile/266130), Wolff AC, Weigelt B, Reis-Filho JS, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Prat A, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128), **Rimawi MF**. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109. PMID: [37195235](//www.ncbi.nlm.nih.gov/pubmed/37195235); PMCID: [PMC10923553](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10923553).

Citations:
[2](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/37195235/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  10. Fu X, Pereira R, [Liu CC](https://profiles.viictr.org/profile/31721876), De Angelis C, Shea MJ, Nanda S, Qin L, Mitchell T, Cataldo ML, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), Sethunath V, Giuliano M, [Gutierrez C](https://profiles.viictr.org/profile/265496), Gyorffy B, Trivedi MV, Cohen O, Wagle N, Nardone A, Jeselsohn R, **Rimawi MF** , Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. Cell Rep. 2023 Aug 29; 42(8):112821. PMID: [37467106](//www.ncbi.nlm.nih.gov/pubmed/37467106).

Citations:  Fields:

Cel Cell BiologyMol Molecular Biology

  11. Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, **Rimawi MF** , Westbrook KE, Buys SS. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO Oncol Pract. 2023 08; 19(8):539-546. PMID: [37207306](//www.ncbi.nlm.nih.gov/pubmed/37207306); PMCID: [PMC10424906](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10424906).

Citations:
[2](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/37207306/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  12. Gradishar WJ, O'Regan R, **Rimawi MF** , Nordstrom JL, Rosales MK, Rugo HS. Margetuximab in HER2-positive metastatic breast cancer. Future Oncol. 2023 May; 19(16):1099-1112. PMID: [37170847](//www.ncbi.nlm.nih.gov/pubmed/37170847).

Citations:
[1](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/37170847/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  13. Arpino G, de la Haba Rodr?guez J, Ferrero JM, De Placido S, Osborne CK, Klingbiel D, Revelant V, Wohlfarth C, Poppe R, **Rimawi MF** , PERTAIN Study Group. Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. Clin Cancer Res. 2023 04 14; 29(8):1468-1476. PMID: [36716289](//www.ncbi.nlm.nih.gov/pubmed/36716289); PMCID: [PMC10102835](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10102835).

Citations:  Fields:

Neo Neoplasms

Translation:Humans

  14. Alkim E, Dowst H, DiCarlo J, Dobrolecki LE, Hern?ndez-Herrera A, Hormuth DA, Liao Y, McOwiti A, [Pautler R](https://profiles.viictr.org/profile/267744), **Rimawi M** , Roark A, Srinivasan RR, Virostko J, Zhang B, Zheng F, Rubin DL, Yankeelov TE, Lewis MT. Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials. Tomography. 2023 04 10; 9(2):810-828. PMID: [37104137](//www.ncbi.nlm.nih.gov/pubmed/37104137); PMCID: [PMC10144684](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10144684).

Citations:
[1](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/37104137/citedby/) Fields:

Dia Diagnostic Imaging

Translation:Humans

  15. Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, **Rimawi MF** , Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, [Tayob N](https://profiles.viictr.org/profile/18883240), Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VA. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. medRxiv. 2023 Mar 08. PMID: [36945501](//www.ncbi.nlm.nih.gov/pubmed/36945501); PMCID: [PMC10029037](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10029037).

Citations:

  16. Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, Sanders ME, [Creighton CJ](https://profiles.viictr.org/profile/265729), Bowen J, Leraas K, Burns RT, Coppens S, Wheless A, Rezk S, Garrett AL, Parker JS, Foy KK, Shen H, Park BH, Krop I, Anders C, [Gastier-Foster J](https://profiles.viictr.org/profile/29494220), **Rimawi MF** , Nanda R, Lin NU, Isaacs C, Marcom PK, Storniolo AM, Couch FJ, Chandran U, Davis M, Silverstein J, Ropelewski A, Liu MC, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Norton L, Richardson AL, [Symmans WF](https://profiles.viictr.org/profile/12583744), Wolff AC, Davidson NE, Carey LA, Lee AV, Balko JM, Hoadley KA, Laird PW, Mardis ER, King TA, AURORA US Network, Perou CM. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023 01; 4(1):128-147. PMID: [36585450](//www.ncbi.nlm.nih.gov/pubmed/36585450); PMCID: [PMC9886551](//www.ncbi.nlm.nih.gov/pmc/articles/PMC9886551).

Citations:
[9](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/36585450/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  17. Petrosyan V, Dobrolecki LE, Thistlethwaite L, Lewis AN, Sallas C, Srinivasan RR, [Lei JT](https://profiles.viictr.org/profile/6998694), Kovacevic V, Obradovic P, Ellis MJ, Osborne CK, **Rimawi MF** , Pavlick A, Shafaee MN, Dowst H, Jain A, Saltzman AB, [Malovannaya A](https://profiles.viictr.org/profile/3010185), Marangoni E, Welm AL, Welm BE, Li S, Wulf GM, Sonzogni O, Huang C, Vasaikar S, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Zhang B, [Milosavljevic A](https://profiles.viictr.org/profile/268148), Lewis MT. Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. iScience. 2023 Jan 20; 26(1):105799. PMID: [36619972](//www.ncbi.nlm.nih.gov/pubmed/36619972); PMCID: [PMC9813793](//www.ncbi.nlm.nih.gov/pmc/articles/PMC9813793).

Citations:
[4](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/36619972/citedby/)

  18. [Anurag M](https://profiles.viictr.org/profile/15619466), Jaehnig EJ, Krug K, [Lei JT](https://profiles.viictr.org/profile/6998694), Bergstrom EJ, Kim BJ, Vashist TD, Huynh AMT, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, [Gibbs RA](https://profiles.viictr.org/profile/269695), [Muzny DM](https://profiles.viictr.org/profile/268028), Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, [Nangia JR](https://profiles.viictr.org/profile/266130), Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, [Echeverria GV](https://profiles.viictr.org/profile/29680397), [Miles G](https://profiles.viictr.org/profile/18892308), **Rimawi MF** , Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605. PMID: [36001024](//www.ncbi.nlm.nih.gov/pubmed/36001024); PMCID: [PMC9627136](//www.ncbi.nlm.nih.gov/pmc/articles/PMC9627136).

Citations:

  19. [Hoyos V](https://profiles.viictr.org/profile/23479202), [Vasileiou S](https://profiles.viictr.org/profile/22016531), Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, [Lulla S](https://profiles.viictr.org/profile/34811365), Robertson C, Foreman C, Wang T, Bulsara S, [Lapteva N](https://profiles.viictr.org/profile/269143), [Grilley B](https://profiles.viictr.org/profile/266987), Ellis M, Osborne CK, Coscio A, [Nangia J](https://profiles.viictr.org/profile/266130), [Heslop HE](https://profiles.viictr.org/profile/269811), [Rooney CM](https://profiles.viictr.org/profile/268355), Vera JF, [Lulla P](https://profiles.viictr.org/profile/3010220), **Rimawi M** , [Leen AM](https://profiles.viictr.org/profile/268626). Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221107113. PMID: [35860837](//www.ncbi.nlm.nih.gov/pubmed/35860837); PMCID: [PMC9290161](//www.ncbi.nlm.nih.gov/pmc/articles/PMC9290161).

Citations:

  20. Sanchez KG, [Nangia JR](https://profiles.viictr.org/profile/266130), [Schiff R](https://profiles.viictr.org/profile/269128), **Rimawi MF**. Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229. PMID: [35737918](//www.ncbi.nlm.nih.gov/pubmed/35737918).

Citations:  Fields:

Neo Neoplasms

  21. Tarantino P, [Tayob N](https://profiles.viictr.org/profile/18883240), Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, **Rimawi M** , Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM, Barroso-Sousa R. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18. PMID: [35173164](//www.ncbi.nlm.nih.gov/pubmed/35173164); PMCID: [PMC8850608](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8850608).

Citations:

  22. Dowsett M, Kilburn L, **Rimawi MF** , Osborne CK, Pogue-Geile K, Liu Y, Jacobs SA, Finnigan M, Puhalla S, Dodson A, Martins V, Cheang M, Perry S, Holcombe C, Turner N, Swift C, Bliss JM, Johnston S, PALLET trialists. Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer. Clin Cancer Res. 2022 01 01; 28(1):163-174. PMID: [34645649](//www.ncbi.nlm.nih.gov/pubmed/34645649); PMCID: [PMC9632606](//www.ncbi.nlm.nih.gov/pmc/articles/PMC9632606).

Citations:  Fields:

Neo Neoplasms

Translation:Humans

  23. [Nangia JR](https://profiles.viictr.org/profile/266130), **Rimawi MF**. Breast Cancer Prevention: Where Are We? JCO Oncol Pract. 2021 12; 17(12):720-722. PMID: [34618555](//www.ncbi.nlm.nih.gov/pubmed/34618555).

Citations:  Fields:

Neo Neoplasms

Translation:Humans

  24. Mouabbi JA, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128), **Rimawi MF**. Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Breast Cancer Res Treat. 2021 Nov; 190(2):189-201. PMID: [34515904](//www.ncbi.nlm.nih.gov/pubmed/34515904).

Citations:
[1](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34515904/citedby/) Fields:

Neo Neoplasms

Translation:HumansCells

  25. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), Nanda S, Qin L, Sethunath V, Wang T, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, **Rimawi MF** , Jansen VM, Jeselsohn R, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4939. PMID: [34470810](//www.ncbi.nlm.nih.gov/pubmed/34470810).

Citations:  Fields:

Neo Neoplasms

  26. Ademuyiwa FO, Chen I, Luo J, **Rimawi MF** , Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Rearden TP, Hernandez-Aya LF, Roshal A, Clifton K, Opyrchal M, Akintola-Ogunremi O, Lee BH, Ferrando-Martinez S, Church SE, [Anurag M](https://profiles.viictr.org/profile/15619466), Ellis MJ, Gao F, Gillanders W, Griffith OL, Griffith M. Immunogenomic?profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Aug; 189(1):187-202. PMID: [34173924](//www.ncbi.nlm.nih.gov/pubmed/34173924); PMCID: [PMC8443324](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8443324).

Citations:
[6](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34173924/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  27. Ruddy KJ, Zheng Y, [Tayob N](https://profiles.viictr.org/profile/18883240), Hu J, Dang CT, Yardley DA, Isakoff SJ, [Valero VV](https://profiles.viictr.org/profile/12582911), Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, **Rimawi M** , Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110. PMID: [34120223](//www.ncbi.nlm.nih.gov/pubmed/34120223).

Citations:
[4](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34120223/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  28. Mouabbi JA, Chand M, Asghar IA, Sakhi R, Ockner D, Dul CL, Hadid T, Aref A, **Rimawi MF** , [Hoyos V](https://profiles.viictr.org/profile/23479202). Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone. Cancer Med. 2021 07; 10(14):4790-4795. PMID: [34080777](//www.ncbi.nlm.nih.gov/pubmed/34080777); PMCID: [PMC8290225](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8290225).

Citations:
[2](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34080777/citedby/) Fields:

Neo Neoplasms

Translation:HumansCells

  29. Tolaney SM, [Tayob N](https://profiles.viictr.org/profile/18883240), Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, **Rimawi M** , Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385. PMID: [34077270](//www.ncbi.nlm.nih.gov/pubmed/34077270).

Citations:
[14](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34077270/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  30. [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), [Gutierrez C](https://profiles.viictr.org/profile/265496), Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, [Nagi C](https://profiles.viictr.org/profile/6998780), [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), **Rimawi MF** , Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer. 2021 May 27; 7(1):63. PMID: [34045483](//www.ncbi.nlm.nih.gov/pubmed/34045483); PMCID: [PMC8159999](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8159999).

Citations:
[1](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34045483/citedby/)

  31. Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, **Rimawi M** , Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol. 2021 07 10; 39(20):2247-2256. PMID: [33999652](//www.ncbi.nlm.nih.gov/pubmed/33999652); PMCID: [PMC8260904](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8260904).

Citations:
[4](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33999652/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  32. Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, Rognoni C, Di Leo A, Locci M, Del Mastro L, Puglisi F, Conte P, De Laurentiis M, Pusztai L, **Rimawi MF** , [Schiff R](https://profiles.viictr.org/profile/269128), Arpino G, De Placido S, Prat A, Generali D, Jerusalem G. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers (Basel). 2021 Mar 22; 13(6). PMID: [33810205](//www.ncbi.nlm.nih.gov/pubmed/33810205); PMCID: [PMC8004645](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8004645).

Citations:
[4](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33810205/citedby/)

  33. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), Nanda S, Qin L, Sethunath V, Wang T, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, **Rimawi MF** , Jansen VM, Jeselsohn R, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882. PMID: [33536276](//www.ncbi.nlm.nih.gov/pubmed/33536276); PMCID: [PMC8628647](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8628647).

Citations:
[11](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33536276/citedby/) Fields:

Neo Neoplasms

Translation:HumansCells

  34. Higashiyama N, [Nangia J](https://profiles.viictr.org/profile/266130), Shafaee MN, Chen N, [Michael BL](https://profiles.viictr.org/profile/268573), **Rimawi M** , [Hoyos V](https://profiles.viictr.org/profile/23479202). Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. Curr Probl Cancer Case Rep. 2020 Dec 15; 2. PMID: [34505091](//www.ncbi.nlm.nih.gov/pubmed/34505091); PMCID: [PMC8425325](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8425325).

Citations:

  35. Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, **Rimawi M** , Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020 11; 31(11):1518-1525. PMID: [32798689](//www.ncbi.nlm.nih.gov/pubmed/32798689); PMCID: [PMC8437015](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8437015).

Citations:
[14](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32798689/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  36. Satpathy S, Jaehnig EJ, Krug K, Kim BJ, Saltzman AB, Chan DW, Holloway KR, [Anurag M](https://profiles.viictr.org/profile/15619466), Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar SV, Mutch D, Watson MA, Ma C, Ademuyiwa FO, **Rimawi MF** , [Schiff R](https://profiles.viictr.org/profile/269128), Hoog J, Jacobs S, [Malovannaya A](https://profiles.viictr.org/profile/3010185), Hyslop T, Clauser KR, Mani DR, Perou CM, Miles G, Zhang B, Gillette MA, Carr SA, Ellis MJ. Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020 Jan 27; 11(1):532. PMID: [31988290](//www.ncbi.nlm.nih.gov/pubmed/31988290); PMCID: [PMC6985126](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6985126).

Citations:
[19](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31988290/citedby/) Fields:

Bio BiologySci Science

Translation:HumansCells

  37. Schettini F, Conte B, Rognoni C, Griguolo G, Guarneri V, Conte PF, Locci M, Brase JC, Gonzalez-Farre B, Villagrasa P, De Placido S, [Schiff R](https://profiles.viictr.org/profile/269128), [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), **Rimawi MF** , Osborne CK, Perou CM, Carey LA, Pascual T, Chic N, Bras?-Maristany F, Galv?n P, Mart?nez O, Adamo B, Vidal M, Mu?oz M, Fern?ndez-Martinez A, Pernas S, Prat A. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2020 Mar; 84:101965. PMID: [32000054](//www.ncbi.nlm.nih.gov/pubmed/32000054); PMCID: [PMC7230134](//www.ncbi.nlm.nih.gov/pmc/articles/PMC7230134).

Citations:
[21](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32000054/citedby/) Fields:

Ant Antineoplastic AgentsNeo Neoplasms

Translation:Humans

  38. De Angelis C, [Gutierrez C](https://profiles.viictr.org/profile/265496), Llombart-Cussac A, Wang T, Rexer B, Forero A, Wolff AC, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), Krop I, Pavlick AC, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, [Schiff R](https://profiles.viictr.org/profile/269128), Guarneri V, Osborne CK, **Rimawi MF** , Prat A, Pascual T, Cort?s J, Par? L, Morales S, Adamo B, Bras?-Maristany F, Vidal M, Galv?n P, Bermejo B. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54. PMID: [31037288](//www.ncbi.nlm.nih.gov/pubmed/31037288); PMCID: [PMC7850037](//www.ncbi.nlm.nih.gov/pmc/articles/PMC7850037).

Citations:
[38](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31037288/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  39. Goutsouliak K, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), Sethunath V, De Angelis C, Osborne CK, **Rimawi MF** , [Schiff R](https://profiles.viictr.org/profile/269128). Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020 04; 17(4):233-250. PMID: [31836877](//www.ncbi.nlm.nih.gov/pubmed/31836877); PMCID: [PMC8023395](//www.ncbi.nlm.nih.gov/pmc/articles/PMC8023395).

Citations:
[51](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31836877/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  40. Fu X, Pereira R, De Angelis C, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, [Gutierrez C](https://profiles.viictr.org/profile/265496), Chamness GC, [Feng Q](https://profiles.viictr.org/profile/267850), [O'Malley BW](https://profiles.viictr.org/profile/269511), Selenica P, Weigelt B, Reis-Filho JS, Cohen O, Wagle N, Nardone A, Jeselsohn R, Brown M, **Rimawi MF** , Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc Natl Acad Sci U S A. 2019 Dec 26; 116(52):26823-26834. PMID: [31826955](//www.ncbi.nlm.nih.gov/pubmed/31826955); PMCID: [PMC6936436](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6936436).

Citations:
[34](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31826955/citedby/) Fields:

Sci Science

  41. **Rimawi MF** , Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, [Nangia JR](https://profiles.viictr.org/profile/266130), Jiralerspong S, Pavlick A, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), De Angelis C, [Gutierrez C](https://profiles.viictr.org/profile/265496), [Schiff R](https://profiles.viictr.org/profile/269128), [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Osborne CK, Translational Breast Cancer Research Consortium. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827. PMID: [31662331](//www.ncbi.nlm.nih.gov/pubmed/31662331).

Citations:
[14](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31662331/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  42. De Angelis C, [Nagi C](https://profiles.viictr.org/profile/6998780), Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), [Trivedi MV](https://profiles.viictr.org/profile/270103), Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, [Gutierrez C](https://profiles.viictr.org/profile/265496), Osborne CK, **Rimawi MF** , [Schiff R](https://profiles.viictr.org/profile/269128). Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745. PMID: [31653641](//www.ncbi.nlm.nih.gov/pubmed/31653641); PMCID: [PMC7002194](//www.ncbi.nlm.nih.gov/pmc/articles/PMC7002194).

Citations:
[13](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31653641/citedby/) Fields:

Neo Neoplasms

Translation:HumansCellsCTClinical Trials

  43. Thangavel H, De Angelis C, Vasaikar S, Bhat R, Jolly MK, [Nagi C](https://profiles.viictr.org/profile/6998780), [Creighton CJ](https://profiles.viictr.org/profile/265729), Chen F, Dobrolecki LE, George JT, Kumar T, Abdulkareem NM, Mao S, Nardone A, **Rimawi M** , Osborne CK, [Lewis MT](https://profiles.viictr.org/profile/267000), Levine H, Zhang B, [Schiff R](https://profiles.viictr.org/profile/269128), Giuliano M, [Trivedi MV](https://profiles.viictr.org/profile/270103). A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. J Clin Med. 2019 10 24; 8(11). PMID: [31652963](//www.ncbi.nlm.nih.gov/pubmed/31652963); PMCID: [PMC6912280](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6912280).

Citations:
[14](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31652963/citedby/)

  44. Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, [Ibrahim N](https://profiles.viictr.org/profile/12582894), Moynihan TJ, [Nangia J](https://profiles.viictr.org/profile/266130), Tung N, Burns R, **Rimawi MF** , Krop IE, Wolff AC, Winer EP, Lin NU, Translational Breast Cancer Research Consortium (TBCRC), Gimenez-Cassina Lopez B. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2. PMID: [31558424](//www.ncbi.nlm.nih.gov/pubmed/31558424); PMCID: [PMC7035200](//www.ncbi.nlm.nih.gov/pmc/articles/PMC7035200).

Citations:
[6](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31558424/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  45. Sethunath V, Hu H, De Angelis C, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), Qin L, Wang N, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, [Shaw C](https://profiles.viictr.org/profile/269433), Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), [Huang S](https://profiles.viictr.org/profile/267743), **Rimawi MF** , Gray JW, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128), Simon LM. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330. PMID: [31420371](//www.ncbi.nlm.nih.gov/pubmed/31420371); PMCID: [PMC6825570](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6825570).

Citations:
[19](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31420371/citedby/) Fields:

Cel Cell BiologyMol Molecular BiologyNeo Neoplasms

Translation:HumansCells

  46. Niravath P, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Wang T, Jiralerspong S, [Nangia J](https://profiles.viictr.org/profile/266130), Pavlick A, Ademuyiwa F, Frith A, Ma C, Park H, Rigden C, Suresh R, Ellis M, Kent Osborne C, **Rimawi MF**. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435. PMID: [31218477](//www.ncbi.nlm.nih.gov/pubmed/31218477).

Citations:
[6](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31218477/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  47. Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, [Fuqua SAW](https://profiles.viictr.org/profile/269832), Prat A, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, **Rimawi MF** , Schiff R. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019 06 01; 30(6):927-933. PMID: [30903140](//www.ncbi.nlm.nih.gov/pubmed/30903140); PMCID: [PMC6594453](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6594453).

Citations:
[17](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30903140/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  48. Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, [Ibrahim N](https://profiles.viictr.org/profile/12582894), Moynihan TJ, O'Sullivan CC, [Nangia J](https://profiles.viictr.org/profile/266130), Niravath P, Tung N, Pohlmann PR, Burns R, **Rimawi MF** , Krop IE, Wolff AC, Winer EP, Lin NU, Translational Breast Cancer Research Consortium. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089. PMID: [30860945](//www.ncbi.nlm.nih.gov/pubmed/30860945); PMCID: [PMC6494354](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6494354).

Citations:
[107](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30860945/citedby/)
Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  49. Ramirez AB, Bhat R, Sahay D, De Angelis C, Thangavel H, Hedayatpour S, Dobrolecki LE, Nardone A, Giuliano M, [Nagi C](https://profiles.viictr.org/profile/6998780), **Rimawi M** , Osborne CK, [Lewis MT](https://profiles.viictr.org/profile/267000), Stilwell JL, Kaldjian EP, [Schiff R](https://profiles.viictr.org/profile/269128), [Trivedi MV](https://profiles.viictr.org/profile/270103). Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019 Mar 12; 19(1):220. PMID: [30871481](//www.ncbi.nlm.nih.gov/pubmed/30871481); PMCID: [PMC6419430](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6419430).

Citations:
[9](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30871481/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  50. Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, **Rimawi M** , Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol. 2019 03 20; 37(9):714-722. PMID: [30721110](//www.ncbi.nlm.nih.gov/pubmed/30721110); PMCID: [PMC6424139](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6424139).

Citations:
[14](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30721110/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  51. Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), [Nagi C](https://profiles.viictr.org/profile/6998780), Pilling M, **Rimawi MF** , [Trivedi M](https://profiles.viictr.org/profile/270103), [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Chamness GC, Jeselsohn R, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339. PMID: [30555156](//www.ncbi.nlm.nih.gov/pubmed/30555156); PMCID: [PMC6353941](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6353941).

Citations:
[17](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30555156/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  52. Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF, **Rimawi M** , McIntosh SA, Shalaby I, Stein RC, Thirlwell M, Dolling D, Morden J, Snowdon C, Perry S, Cornman C, Batten LM, Jeffs LK, Dodson A, Martins V, Modi A, Osborne CK, Pogue-Geile KL, Cheang MCU, Wolmark N, Julian TB, Fisher K, MacKenzie M, Wilcox M, Huang Bartlett C, Koehler M, Dowsett M, Bliss JM, Jacobs SA, Provencher L, Robidoux A. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. J Clin Oncol. 2019 01 20; 37(3):178-189. PMID: [30523750](//www.ncbi.nlm.nih.gov/pubmed/30523750).

Citations:
[47](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30523750/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  53. **Rimawi M** , Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G, PERTAIN Study Group. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. J Clin Oncol. 2018 10 01; 36(28):2826-2835. PMID: [30106636](//www.ncbi.nlm.nih.gov/pubmed/30106636).

Citations:
[41](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30106636/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  54. Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, [Katsonis P](https://profiles.viictr.org/profile/3009828), Schmitt E, Chan DW, Li H, Mao S, Petrovic I, [Creighton CJ](https://profiles.viictr.org/profile/265729), [Gutierrez C](https://profiles.viictr.org/profile/265496), Dubrulle J, Stossi F, Tyner JW, [Lichtarge O](https://profiles.viictr.org/profile/269815), Lin CY, Zhang B, Scott KL, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Sun J, Yu X, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128), Christensen JG, Shields DJ, **Rimawi MF** , Ellis MJ, [Shaw CA](https://profiles.viictr.org/profile/269433), [Lewis MT](https://profiles.viictr.org/profile/267000), [Westbrook TF](https://profiles.viictr.org/profile/267742). Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511. PMID: [29578538](//www.ncbi.nlm.nih.gov/pubmed/29578538); PMCID: [PMC6675908](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6675908).

Citations:
[21](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29578538/citedby/) Fields:

Med Medicine (General)Mol Molecular Biology

Translation:HumansAnimalsCells

  55. International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Breast International Group, Wapnir IL, Price KN, Anderson SJ, Robidoux A, Mart?n M, Nortier JWR, Paterson AHG, **Rimawi MF** , L?ng I, Baena-Ca?ada JM, Th?rlimann B, Mamounas EP, Geyer CE, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol. 2018 04 10; 36(11):1073-1079. PMID: [29443653](//www.ncbi.nlm.nih.gov/pubmed/29443653); PMCID: [PMC5891132](//www.ncbi.nlm.nih.gov/pmc/articles/PMC5891132).

Citations:
[29](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29443653/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  56. **Rimawi MF** , De Angelis C, [Contreras A](https://profiles.viictr.org/profile/12582874), Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, [Fuqua SAW](https://profiles.viictr.org/profile/269832), [Gutierrez C](https://profiles.viictr.org/profile/265496), [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, [Schiff R](https://profiles.viictr.org/profile/269128). Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740. PMID: [29110152](//www.ncbi.nlm.nih.gov/pubmed/29110152); PMCID: [PMC5821069](//www.ncbi.nlm.nih.gov/pmc/articles/PMC5821069).

Citations:
[32](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29110152/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  57. Niravath P, Chen B, Chapman JW, [Agarwal SK](https://profiles.viictr.org/profile/267111), Welschhans RL, Bongartz T, Kalari KR, Shepherd LE, Bartlett J, Pritchard K, Gelmon K, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), **Rimawi MF** , Osborne CK, Goss PE, Ingle JN. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer. 2018 02; 18(1):78-87. PMID: [29128193](//www.ncbi.nlm.nih.gov/pubmed/29128193); PMCID: [PMC7469602](//www.ncbi.nlm.nih.gov/pmc/articles/PMC7469602).

Citations:
[9](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29128193/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  58. [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), De Angelis C, Reis-Filho JS, Prat A, **Rimawi MF** , Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128), Pascual T. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast. 2017 Aug; 34 Suppl 1:S19-S26. PMID: [28687441](//www.ncbi.nlm.nih.gov/pubmed/28687441); PMCID: [PMC6050048](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6050048).

Citations:
[21](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28687441/citedby/) Fields:

End EndocrinologyNeo Neoplasms

Translation:HumansCells

  59. Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, [Veeraraghavan J](https://profiles.viictr.org/profile/3010617), Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, [Gutierrez C](https://profiles.viictr.org/profile/265496), [Nagi C](https://profiles.viictr.org/profile/6998780), Geyer FC, Chamness GC, Park BH, [Shaw CA](https://profiles.viictr.org/profile/269433), [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), **Rimawi MF** , Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134. PMID: [28487443](//www.ncbi.nlm.nih.gov/pubmed/28487443); PMCID: [PMC5762201](//www.ncbi.nlm.nih.gov/pmc/articles/PMC5762201).

Citations:
[39](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28487443/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  60. Gastelum GM, Iqbal C, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), **Rimawi MF** , Niravath P. Retrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195. PMID: [28224382](//www.ncbi.nlm.nih.gov/pubmed/28224382).

Citations:  Fields:

Neo Neoplasms

Translation:Humans

  61. [Nangia J](https://profiles.viictr.org/profile/266130), Wang T, Osborne C, Niravath P, Otte K, Papish S, Holmes F, Abraham J, Lacouture M, Courtright J, Paxman R, Rude M, [Hilsenbeck S](https://profiles.viictr.org/profile/268374), Osborne CK, **Rimawi M**. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605. PMID: [28196254](//www.ncbi.nlm.nih.gov/pubmed/28196254).

Citations:
[45](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28196254/citedby/) Fields:

Med Medicine (General)

Translation:HumansPHPublic Health

  62. Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, [Creighton CJ](https://profiles.viictr.org/profile/265729), Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, [Gutierrez C](https://profiles.viictr.org/profile/265496), [Huang S](https://profiles.viictr.org/profile/267743), Edwards DP, [Trivedi MV](https://profiles.viictr.org/profile/270103), **Rimawi MF** , [Lopez-Terrada D](https://profiles.viictr.org/profile/266283), [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Gray JW, Brown M, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609. PMID: [27791031](//www.ncbi.nlm.nih.gov/pubmed/27791031); PMCID: [PMC5087040](//www.ncbi.nlm.nih.gov/pmc/articles/PMC5087040).

Citations:
[61](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27791031/citedby/) Fields:

Sci Science

Translation:HumansCells

  63. Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, **Rimawi MF** , [Hilsenbeck S](https://profiles.viictr.org/profile/268374), [Schiff R](https://profiles.viictr.org/profile/269128), Osborne KC, Letai A, Polyak K. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506. PMID: [27671678](//www.ncbi.nlm.nih.gov/pubmed/27671678); PMCID: [PMC5344673](//www.ncbi.nlm.nih.gov/pmc/articles/PMC5344673).

Citations:
[47](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27671678/citedby/) Fields:

Neo Neoplasms

Translation:HumansCells

  64. Soleja M, **Rimawi MF**. Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions. Curr Probl Cancer. 2016 Mar - Aug; 40(2-4):117-129. PMID: [27839746](//www.ncbi.nlm.nih.gov/pubmed/27839746).

Citations:
[1](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27839746/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimals

  65. Mitri Z, Nanda R, Blackwell K, [Costelloe CM](https://profiles.viictr.org/profile/12583797), Hood I, Wei C, [Brewster AM](https://profiles.viictr.org/profile/12583019), [Ibrahim NK](https://profiles.viictr.org/profile/12582894), [Koenig KB](https://profiles.viictr.org/profile/17439961), Hortobagyi GN, Van Poznak C, **Rimawi MF** , Moulder-Thompson S, Translational Breast Cancer Research Consortium. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clin Cancer Res. 2016 Dec 01; 22(23):5706-5712. PMID: [27166393](//www.ncbi.nlm.nih.gov/pubmed/27166393).

Citations:
[16](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27166393/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  66. Freedman RA, Gelman RS, [Wefel JS](https://profiles.viictr.org/profile/12582955), Melisko ME, [Hess KR](https://profiles.viictr.org/profile/12582910), Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, [Ibrahim N](https://profiles.viictr.org/profile/12582894), Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, **Rimawi MF** , Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52. PMID: [26834058](//www.ncbi.nlm.nih.gov/pubmed/26834058); PMCID: [PMC5070554](//www.ncbi.nlm.nih.gov/pmc/articles/PMC5070554).

Citations:
[64](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26834058/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  67. Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, **Rimawi MF** , Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015 Aug 20; 33(24):2623-31. PMID: [26169615](//www.ncbi.nlm.nih.gov/pubmed/26169615); PMCID: [PMC4534525](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4534525).

Citations:
[17](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26169615/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  68. Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, [Contreras A](https://profiles.viictr.org/profile/12582874), [Gutierrez C](https://profiles.viictr.org/profile/265496), Wang T, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), De Angelis C, Wang NJ, Heiser LM, Gray JW, Pavlick AC, [Trivedi MV](https://profiles.viictr.org/profile/270103), Chamness GC, Chang JC, Osborne CK, **Rimawi MF** , [Schiff R](https://profiles.viictr.org/profile/269128), Lopez-Tarruella S. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003. PMID: [26015514](//www.ncbi.nlm.nih.gov/pubmed/26015514); PMCID: [PMC4558260](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4558260).

Citations:
[39](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26015514/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  69. Giuliano M, Herrera S, Christiny P, [Shaw C](https://profiles.viictr.org/profile/269433), [Creighton CJ](https://profiles.viictr.org/profile/265729), Mitchell T, Bhat R, [Zhang X](https://profiles.viictr.org/profile/269369), Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), [Contreras A](https://profiles.viictr.org/profile/12582874), [Gutierrez C](https://profiles.viictr.org/profile/265496), Jeselsohn RM, **Rimawi MF** , Osborne CK, [Lewis MT](https://profiles.viictr.org/profile/267000), [Schiff R](https://profiles.viictr.org/profile/269128), [Trivedi MV](https://profiles.viictr.org/profile/270103). Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3. PMID: [25572662](//www.ncbi.nlm.nih.gov/pubmed/25572662); PMCID: [PMC4318479](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4318479).

Citations:
[32](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25572662/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  70. Niravath P, [Eble T](https://profiles.viictr.org/profile/267869), [Contreras A](https://profiles.viictr.org/profile/12582874), Li M, Franco LM, **Rimawi M**. Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked. Exp Hematol Oncol. 2015; 4(1):1. PMID: [25671134](//www.ncbi.nlm.nih.gov/pubmed/25671134); PMCID: [PMC4323278](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4323278).

Citations:
[1](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25671134/citedby/)

  71. **Rimawi MF** , De Angelis C, [Schiff R](https://profiles.viictr.org/profile/269128). Resistance to Anti-HER2 Therapies in Breast Cancer. Am Soc Clin Oncol Educ Book. 2015; e157-64. PMID: [25993167](//www.ncbi.nlm.nih.gov/pubmed/25993167).

Citations:
[10](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25993167/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimals

  72. **Rimawi MF** , [Schiff R](https://profiles.viictr.org/profile/269128), [Osborne CK](https://profiles.viictr.org/profile/268375). Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28. PMID: [25587647](//www.ncbi.nlm.nih.gov/pubmed/25587647).

Citations:
[104](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25587647/citedby/)
Fields:

Med Medicine (General)

Translation:Humans

  73. Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, **Rimawi MF** , Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS, Translational Breast Cancer Research Consortium. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 01; 21(5):1098-105. PMID: [25524311](//www.ncbi.nlm.nih.gov/pubmed/25524311).

Citations:
[25](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25524311/citedby/) Fields:

Neo Neoplasms

Translation:HumansCells

  74. **Rimawi MF** , Rozas AA, Caleffi M, [Gutierrez C](https://profiles.viictr.org/profile/265496), Uttenreuther-Fischer MM, Solca F, Osborne CK, Aleixo SB, Nunes de Matos Neto J, Figueira AC, Souza SC, Reiriz AB, Arantes H. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. Clin Breast Cancer. 2015 Apr; 15(2):101-9. PMID: [25537159](//www.ncbi.nlm.nih.gov/pubmed/25537159).

Citations:
[18](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25537159/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  75. Niravath P, Tham YL, [Wang T](https://profiles.viictr.org/profile/3009836), Rodriguez A, Foreman C, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Elledge R, **Rimawi M**. A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. Oncologist. 2015 Jan; 20(1):13. PMID: [25378456](//www.ncbi.nlm.nih.gov/pubmed/25378456); PMCID: [PMC4294610](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4294610).

Citations:
[8](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25378456/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  76. Fu X, [Creighton CJ](https://profiles.viictr.org/profile/265729), Biswal NC, Kumar V, Shea M, Herrera S, [Contreras A](https://profiles.viictr.org/profile/12582874), [Gutierrez C](https://profiles.viictr.org/profile/265496), Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, [Karlin KL](https://profiles.viictr.org/profile/1826677), [Westbrook TF](https://profiles.viictr.org/profile/267742), Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, [Mills GB](https://profiles.viictr.org/profile/12582930), **Rimawi MF** , [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Gray JW, Joshi A, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430. PMID: [25212826](//www.ncbi.nlm.nih.gov/pubmed/25212826); PMCID: [PMC4303114](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4303114).

Citations:
[40](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25212826/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  77. Niravath P, **Rimawi MF** , Osborne CK. Aromatase inhibitor adverse effects: are we sweeping them under the rug? J Clin Oncol. 2014 Nov 20; 32(33):3779. PMID: [25154832](//www.ncbi.nlm.nih.gov/pubmed/25154832).

Citations:
[1](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25154832/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  78. Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, **Rimawi M** , Conte P, Jin JY. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014 Aug; 74(2):399-410. PMID: [24939213](//www.ncbi.nlm.nih.gov/pubmed/24939213); PMCID: [PMC4112050](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4112050).

Citations:
[26](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24939213/citedby/) Fields:

Ant Antineoplastic AgentsNeo Neoplasms

Translation:Humans

  79. Crew KD, Ho KA, Brown P, Greenlee H, [Bevers TB](https://profiles.viictr.org/profile/12583704), [Arun B](https://profiles.viictr.org/profile/12583365), Sneige N, Hudis C, McArthur HL, Chang J, **Rimawi M** , Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet. 2015 Jun; 28(3):272-82. PMID: [24646362](//www.ncbi.nlm.nih.gov/pubmed/24646362); PMCID: [PMC4205214](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4205214).

Citations:
[12](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24646362/citedby/) Fields:

Nut Nutritional Sciences

Translation:HumansCells

  80. Morrison G, Fu X, Shea M, Nanda S, Giuliano M, [Wang T](https://profiles.viictr.org/profile/3009836), Klinowska T, Osborne CK, **Rimawi MF** , [Schiff R](https://profiles.viictr.org/profile/269128). Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat. 2014 Apr; 144(2):263-72. PMID: [24554387](//www.ncbi.nlm.nih.gov/pubmed/24554387); PMCID: [PMC4030601](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4030601).

Citations:
[32](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24554387/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  81. Aebi S, Gelber S, Anderson SJ, Nortier JW, Paterson AH, **Rimawi MF** , Murray E, Mamounas EP, Geyer CE, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL, CALOR investigators, L?ng I, Robidoux A, Mart?n M, Ca?ada JM, Th?rlimann B. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014 Feb; 15(2):156-63. PMID: [24439313](//www.ncbi.nlm.nih.gov/pubmed/24439313); PMCID: [PMC3982874](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3982874).

Citations:
[56](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24439313/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  82. Parma J, Pavlick A, [Schiff R](https://profiles.viictr.org/profile/269128), Osborne CK, Chang JC, **Rimawi M** , [Trivedi MV](https://profiles.viictr.org/profile/270103). Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer. Pharmacotherapy. 2013 Oct; 33(10):1126-9. PMID: [23744830](//www.ncbi.nlm.nih.gov/pubmed/23744830).

Citations:
[3](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23744830/citedby/) Fields:

Dru Drug Therapy

Translation:HumansCTClinical Trials

  83. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, [Schiff R](https://profiles.viictr.org/profile/269128), Giuliano M, Wong H, Fuqua SW, [Contreras A](https://profiles.viictr.org/profile/12582874), [Gutierrez C](https://profiles.viictr.org/profile/265496), Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Chen ES, Zuloaga P, [Shaw CA](https://profiles.viictr.org/profile/269433), **Rimawi MF** , Perou CM, [Mills GB](https://profiles.viictr.org/profile/12582930), Chang JC, [Lewis MT](https://profiles.viictr.org/profile/267000). A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97. PMID: [23737486](//www.ncbi.nlm.nih.gov/pubmed/23737486); PMCID: [PMC3732575](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3732575).

Citations:
[223](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23737486/citedby/)
Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  84. Wolfswinkel EM, Lopez SN, Weathers WM, Qashqai S, [Wang T](https://profiles.viictr.org/profile/3009836), [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), **Rimawi MF** , Heller L. Predictors of post-mastectomy reconstruction in an underserved population. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):763-9. PMID: [23582504](//www.ncbi.nlm.nih.gov/pubmed/23582504).

Citations:
[5](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23582504/citedby/) Fields:

Gen General Surgery

Translation:Humans

  85. **Rimawi MF** , Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, [Wang T](https://profiles.viictr.org/profile/3009836), [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), [Gutierrez C](https://profiles.viictr.org/profile/265496), [Schiff R](https://profiles.viictr.org/profile/269128), Osborne CK, Chang JC. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31. PMID: [23569315](//www.ncbi.nlm.nih.gov/pubmed/23569315); PMCID: [PMC3641695](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3641695).

Citations:
[94](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23569315/citedby/) Fields:

Neo Neoplasms

Translation:HumansCellsCTClinical Trials

  86. Malorni L, [Shetty PB](https://profiles.viictr.org/profile/35549192), De Angelis C, [Hilsenbeck S](https://profiles.viictr.org/profile/268374), **Rimawi MF** , Elledge R, Osborne CK, De Placido S, Arpino G. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012 Dec; 136(3):795-804. PMID: [23124476](//www.ncbi.nlm.nih.gov/pubmed/23124476); PMCID: [PMC3513514](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3513514).

Citations:
[74](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23124476/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  87. Crew KD, [Brown P](https://profiles.viictr.org/profile/12582793), Greenlee H, [Bevers TB](https://profiles.viictr.org/profile/12583704), [Arun B](https://profiles.viictr.org/profile/12583365), Hudis C, McArthur HL, Chang J, **Rimawi M** , Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54. PMID: [22827973](//www.ncbi.nlm.nih.gov/pubmed/22827973); PMCID: [PMC3816771](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3816771).

Citations:
[41](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22827973/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  88. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, **Rimawi MF** , Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23. PMID: [22665533](//www.ncbi.nlm.nih.gov/pubmed/22665533); PMCID: [PMC3413275](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3413275).

Citations:
[219](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22665533/citedby/)
Fields:

Neo Neoplasms

Translation:HumansCellsCTClinical Trials

  89. [Chen AC](https://profiles.viictr.org/profile/30445132), Migliaccio I, **Rimawi M** , Lopez-Tarruella S, [Creighton CJ](https://profiles.viictr.org/profile/265729), Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93. PMID: [22644656](//www.ncbi.nlm.nih.gov/pubmed/22644656); PMCID: [PMC3408244](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3408244).

Citations:
[15](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22644656/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  90. Bilen MA, [Laucirica R](https://profiles.viictr.org/profile/266515), **Rimawi MF** , [Nangia JR](https://profiles.viictr.org/profile/266130), [Cyprus GS](https://profiles.viictr.org/profile/267561). Jejunal intussusception due to malignant phyllodes tumor of the breast. Clin Breast Cancer. 2012 Jun; 12(3):219-21. PMID: [22381472](//www.ncbi.nlm.nih.gov/pubmed/22381472).

Citations:
[4](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22381472/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  91. **Rimawi MF** , [Osborne CK](https://profiles.viictr.org/profile/268375). Breast Cancer: Blocking both driver and escape pathways improves outcomes. Nat Rev Clin Oncol. 2012 Feb 14; 9(3):133-4. PMID: [22330685](//www.ncbi.nlm.nih.gov/pubmed/22330685).

Citations:
[8](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22330685/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  92. **Rimawi M** , [Hilsenbeck SG](https://profiles.viictr.org/profile/268374). Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? J Clin Oncol. 2012 Feb 01; 30(4):453-8. PMID: [22215751](//www.ncbi.nlm.nih.gov/pubmed/22215751).

Citations:
[9](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22215751/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  93. Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Phillips GL, Chamness GC, **Rimawi MF** , Osborne CK, Schiff R. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121. PMID: [22123186](//www.ncbi.nlm.nih.gov/pubmed/22123186); PMCID: [PMC3326563](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3326563).

Citations:
[119](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22123186/citedby/)
Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  94. Huang C, Park CC, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Ward R, **Rimawi MF** , Wang YC, Shou J, Bissell MJ, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). ?1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31; 13(4):R84. PMID: [21884573](//www.ncbi.nlm.nih.gov/pubmed/21884573); PMCID: [PMC3236347](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3236347).

Citations:
[86](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21884573/citedby/) Fields:

Neo Neoplasms

Translation:HumansCells

  95. Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, **Rimawi M** , Cai WY, [Hilsenbeck S](https://profiles.viictr.org/profile/268374), [Fuqua S](https://profiles.viictr.org/profile/269832), Elledge R. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27. PMID: [21792626](//www.ncbi.nlm.nih.gov/pubmed/21792626); PMCID: [PMC4477822](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4477822).

Citations:
[21](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21792626/citedby/) Fields:

Neo Neoplasms

Translation:HumansCTClinical Trials

  96. Litzenburger BC, [Creighton CJ](https://profiles.viictr.org/profile/265729), Tsimelzon A, Chan BT, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), [Wang T](https://profiles.viictr.org/profile/3009836), Carboni JM, Gottardis MM, Huang F, Chang JC, [Lewis MT](https://profiles.viictr.org/profile/267000), **Rimawi MF** , Lee AV. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27. PMID: [21177763](//www.ncbi.nlm.nih.gov/pubmed/21177763); PMCID: [PMC3073089](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3073089).

Citations:
[65](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21177763/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  97. **Rimawi MF** , Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, [Gutierrez C](https://profiles.viictr.org/profile/265496), [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61. PMID: [21138857](//www.ncbi.nlm.nih.gov/pubmed/21138857); PMCID: [PMC3060302](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3060302).

Citations:
[45](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21138857/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  98. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Huang J, **Rimawi M** , [Schiff R](https://profiles.viictr.org/profile/269128), Arteaga C, Osborne CK, Chang JC. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73. PMID: [21135276](//www.ncbi.nlm.nih.gov/pubmed/21135276); PMCID: [PMC3058274](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3058274).

Citations:
[123](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21135276/citedby/)
Fields:

Neo Neoplasms

Translation:HumansCells

  99. Rodriguez AA, Makris A, Wu MF, **Rimawi M** , Froehlich A, Dave B, [Hilsenbeck SG](https://profiles.viictr.org/profile/268374), Chamness GC, [Lewis MT](https://profiles.viictr.org/profile/267000), Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010 Aug; 123(1):189-96. PMID: [20582464](//www.ncbi.nlm.nih.gov/pubmed/20582464).

Citations:
[30](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20582464/citedby/) Fields:

Neo Neoplasms

Translation:HumansCells

  100. **Rimawi MF** , [Shetty PB](https://profiles.viictr.org/profile/35549192), Weiss HL, [Schiff R](https://profiles.viictr.org/profile/269128), Osborne CK, Chamness GC, Elledge RM. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 2010 Mar 01; 116(5):1234-42. PMID: [20082448](//www.ncbi.nlm.nih.gov/pubmed/20082448); PMCID: [PMC2829330](//www.ncbi.nlm.nih.gov/pmc/articles/PMC2829330).

Citations:
[91](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20082448/citedby/) Fields:

Neo Neoplasms

Translation:Humans

  101. Friedman LC, Barber CR, Chang J, Tham YL, [Kalidas M](https://profiles.viictr.org/profile/21983619), **Rimawi MF** , Dulay MF, Elledge R. Self-blame, self-forgiveness, and spirituality in breast cancer survivors in a public sector setting. J Cancer Educ. 2010 Sep; 25(3):343-8. PMID: [20186521](//www.ncbi.nlm.nih.gov/pubmed/20186521).

Citations:
[6](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20186521/citedby/) Fields:

Edu EducationNeo Neoplasms

Translation:Humans

  102. Massarweh S, [Osborne CK](https://profiles.viictr.org/profile/268375), [Creighton CJ](https://profiles.viictr.org/profile/265729), Qin L, Tsimelzon A, [Huang S](https://profiles.viictr.org/profile/267743), Weiss H, **Rimawi M** , [Schiff R](https://profiles.viictr.org/profile/269128). Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33. PMID: [18245484](//www.ncbi.nlm.nih.gov/pubmed/18245484).

Citations:
[215](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18245484/citedby/)
Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  103. Arpino G, [Gutierrez C](https://profiles.viictr.org/profile/265496), Weiss H, **Rimawi M** , Massarweh S, Bharwani L, De Placido S, Osborne CK, [Schiff R](https://profiles.viictr.org/profile/269128). Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007 May 02; 99(9):694-705. PMID: [17470737](//www.ncbi.nlm.nih.gov/pubmed/17470737).

Citations:
[85](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/17470737/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  104. Massarweh S, [Osborne CK](https://profiles.viictr.org/profile/268375), Jiang S, Wakeling AE, **Rimawi M** , Mohsin SK, [Hilsenbeck S](https://profiles.viictr.org/profile/268374), [Schiff R](https://profiles.viictr.org/profile/269128). Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73. PMID: [16912207](//www.ncbi.nlm.nih.gov/pubmed/16912207).

Citations:
[65](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/16912207/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  105. [Schiff R](https://profiles.viictr.org/profile/269128), Massarweh SA, Shou J, Bharwani L, Arpino G, **Rimawi M** , [Osborne CK](https://profiles.viictr.org/profile/268375). Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005 Nov; 56 Suppl 1:10-20. PMID: [16273359](//www.ncbi.nlm.nih.gov/pubmed/16273359).

Citations:
[66](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/16273359/citedby/) Fields:

Ant Antineoplastic AgentsNeo Neoplasms

Translation:HumansCells

This graph shows the total number of publications by year. To see the data as
text, click here.

![Bar chart showing 105 publications over 19 distinct years, with a maximum of
12 publications in 2019 and
2021](//chart.googleapis.com/chart?chs=595x100&chf=bg,s,ffffff|c,s,ffffff&chxt=x,y&chxl=0:|'94||'96||'98||'00||'02||'04||'06||'08||'10||'12||'14||'16||'18||'20||'22||'24|1:|0|12&cht=bvs&chd=t:0,0,0,0,0,0,0,0,0,0,0,8,8,8,8,0,50,25,58,33,75,50,42,50,42,100,42,100,50,92,33&chdl=Publications&chco=80B1D3&chbh=10)

This graph shows the total number of publications by year. To return to the
graph, click here.

Year| Publications  
---|---  
2005| 1  
2006| 1  
2007| 1  
2008| 1  
2010| 6  
2011| 3  
2012| 7  
2013| 4  
2014| 9  
2015| 6  
2016| 5  
2017| 6  
2018| 5  
2019| 12  
2020| 5  
2021| 12  
2022| 6  
2023| 11  
2024| 4  
  
This graph shows the number and percent of publications by field. Fields are
based on how the National Library of Medicine (NLM) classifies the
publications' journals and might not represent the specific topics of the
publications. Note that an individual publication can be assigned to more than
one field. As a result, the publication counts in this graph might add up to
more than the number of publications the person has written. To see the data
as text, click here.

This graph shows the number and percent of publications by field. Fields are
based on how the National Library of Medicine (NLM) classifies the
publications' journals and might not represent the specific topics of the
publications. Note that an individual publication can be assigned to more than
one field. As a result, the publication counts in this graph might add up to
more than the number of publications the person has written. To see the data
as text, click here.

Start with: newest oldest Include: line numbers double spacing all authors
publication IDs

RIMAWI's Networks

Click the

Explore

buttons for more information and interactive visualizations!

Concepts (315)
![](https://profiles.viictr.org/profile/modules/passivelist/Images/info.png)

Derived automatically from this person's publications.

  * [Receptor, ErbB-2](https://profiles.viictr.org/profile/250511)
  * [Breast Neoplasms](https://profiles.viictr.org/profile/256408)
  * [Trastuzumab](https://profiles.viictr.org/profile/27544440)
  * [Quinazolines](https://profiles.viictr.org/profile/245489)
  * [Receptors, Estrogen](https://profiles.viictr.org/profile/261563)

[Explore](https://profiles.viictr.org/profile/269416/198)

_

Co-Authors (76)
![](https://profiles.viictr.org/profile/modules/passivelist/Images/info.png)

People in Profiles who have published with this person.

  * [SCHIFF, RACHEL](https://profiles.viictr.org/profile/269128)
  * [HILSENBECK, SUSAN](https://profiles.viictr.org/profile/268374)
  * [NANGIA, JULIE](https://profiles.viictr.org/profile/266130)
  * [VEERARAGHAVAN, JAMUNARANI](https://profiles.viictr.org/profile/3010617)
  * [GUTIERREZ, CAROLINA](https://profiles.viictr.org/profile/265496)

[Explore](https://profiles.viictr.org/profile/269416/345)

_

Similar People (60)
![](https://profiles.viictr.org/profile/modules/passivelist/Images/info.png)

People who share similar concepts with this person.

  * [MERIC-BERNSTAM, FUNDA](https://profiles.viictr.org/profile/12583329)
  * [MITTENDORF, ELIZABETH ANN](https://profiles.viictr.org/profile/12583070)
  * [KANTARJIAN, HAGOP M](https://profiles.viictr.org/profile/12582901)
  * [UENO, NAOTO T](https://profiles.viictr.org/profile/12582890)
  * [HUNT, KELLY K](https://profiles.viictr.org/profile/12582914)

[Explore](https://profiles.viictr.org/profile/269416/476)

_

Same Department [ ![Expand
Description](https://profiles.viictr.org/Framework/Images/info.png)
](JavaScript:toggleVisibility\('sdDescript'\);)

People who are also in this person's primary department.

  * [HILSENBECK, SUSAN](https://profiles.viictr.org/profile/268374)
  * [KEMNADE, JAN](https://profiles.viictr.org/profile/17411292)
  * [LIN, FANG-TSYR](https://profiles.viictr.org/profile/269919)
  * [SONNET, CORINNE](https://profiles.viictr.org/profile/15317746)
  * [UDDEN, MARK](https://profiles.viictr.org/profile/266554)

[Explore](https://profiles.viictr.org/search/default.aspx?searchtype=people&searchfor=&SearchRequest=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)

_

Physical Neighbors
![](https://profiles.viictr.org/profile/modules/passivelist/Images/info.png)

People whose addresses are nearby this person.

  * [HO, SHIUH-RONG](https://profiles.viictr.org/profile/3009889)
  * [MICHAEL, BINU](https://profiles.viictr.org/profile/268573)
  * [MUSHER, BENJAMIN](https://profiles.viictr.org/profile/266798)
  * [TODD, ROBERT](https://profiles.viictr.org/profile/266047)
  * [YEN, AIHUA](https://profiles.viictr.org/profile/270002)

_

